Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term B7-H1 Antigen. Found 7 abstracts

Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, Sakai H, Albert I, Vergnenegre A, Peters S, Syrigos K, Barlesi F, Reck M, Borghaei H, Brahmer JR, O'Byrne KJ, Geese WJ, Bhagavatheeswaran P, Rabindran SK, Kasinathan RS, Nathan FE, Ramalingam SS. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. The New England journal of medicine. 2019 Sep 28;381(21):2020-31.
Gerson JN, Ramamurthy C, Borghaei H. Managing adverse effects of immunotherapy. Clinical advances in hematology & oncology : H&O. 2018 May;16(5):364-74.   PMCID: Review
Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. European urology oncology. 2018 Aug;1(3):190-8.
Mehra R, Seiwert TY, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Geva R, Chung HC, Lin CC, Aurora-Garg D, Ray A, Pathiraja K, Cheng J, Chow LQ, Haddad R. Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. Br J Cancer. 2018 Jul;119(2):153-9.   PMCID: PMC6048158
Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, Flieder DB, Homer R, West WW, Wu H, Roden AC, Fujimoto J, Yu H, Anders R, Kowalewski A, Rivard C, Rehman J, Batenchuk C, Burns V, Hirsch FR, Wistuba. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncol. 2017 Aug;3(8):1051-8.   PMCID: PMC5650234
Chow LQ, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. J Clin Oncol. 2016 Nov 10;34(32):3838-45.
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term B7-H1 Antigen

B7-H1 Antigen drug therapy pathology adverse effects administration & dosage Aged Middle Aged Male Female Immunological Antineoplastic Agents Adult Lung Neoplasms metabolism Non-Small-Cell Lung Carcinoma immunology genetics Monoclonal Antibodies-Humanized antagonists & inhibitors Monoclonal Antibodies therapeutic use 80 and over Aged Neoplastic Gene Expression Regulation CTLA-4 Antigen Squamous Cell Carcinoma of Head and Neck Cohort Studies biosynthesis Local Neoplasm Recurrence Neoplasm Metastasis Antineoplastic Combined Chemotherapy Protocols Ipilimumab methods Programmed Cell Death 1 Receptor Checkpoint inhibitor Squamous Cell Carcinoma analogs & derivatives Drug Dose-Response Relationship Pneumonia ctla-4 Muscle-invasive Preclinical Drug Evaluation Biological Assay drug effects epidemiology Progression-Free Survival Immunotherapy Reproducibility of Results Survival Analysis Dermatitis Antibodies Epidermal Growth Factor Receptor Head and Neck Neoplasms Urinary Bladder Neoplasms Retrospective Studies Therapy Antineoplastic Agents Cisplatin Disease-Free Survival Bladder cancer Transitional Cell Carcinoma pd-1 Cell Cycle Checkpoints Disease Management Proto-Oncogene Proteins p21(ras) Nivolumab Deoxycytidine Survival Rate Kaplan-Meier Estimate Pemetrexed mortality Protein Kinase Inhibitors Pathologists pd-l1 Drug-Related Side Effects and Adverse Reactions Immunohistochemistry Localized Hepatitis Treatment Hematologic Neoplasms prevention & control Colitis Carboplatin Non-muscle-invasive classification Follow-Up Studies etiology physiology
Last updated on Friday, January 03, 2020